TESARO Inc (NASDAQ:TSRO) has received an average rating of “Hold” from the twenty-eight brokerages that are currently covering the stock, Marketbeat.com reports. Three research analysts have rated the stock with a sell recommendation, nine have given a hold recommendation, fourteen have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price target among analysts that have issued a report on the stock in the last year is $146.73.
TSRO has been the topic of several research analyst reports. Barclays initiated coverage on TESARO in a research report on Monday, October 23rd. They issued an “equal weight” rating and a $135.00 price objective on the stock. ValuEngine downgraded TESARO from a “hold” rating to a “sell” rating in a research report on Tuesday, October 10th. Jefferies Group reaffirmed a “hold” rating and issued a $124.00 price objective on shares of TESARO in a research report on Friday, November 3rd. HC Wainwright reaffirmed a “buy” rating and issued a $158.00 price objective on shares of TESARO in a research report on Thursday, October 26th. Finally, Morgan Stanley reaffirmed an “overweight” rating and issued a $165.00 price objective (down previously from $181.00) on shares of TESARO in a research report on Wednesday, November 8th.
Shares of TESARO (NASDAQ TSRO) traded down $1.79 during trading on Friday, reaching $69.23. The company’s stock had a trading volume of 1,016,449 shares, compared to its average volume of 1,210,000. The company has a market cap of $3,670.00, a P/E ratio of -8.21 and a beta of 1.51. The company has a quick ratio of 4.35, a current ratio of 4.73 and a debt-to-equity ratio of 0.34. TESARO has a 12 month low of $59.77 and a 12 month high of $192.94.
In related news, SVP Martin H. Jr. Huber sold 829 shares of the company’s stock in a transaction on Monday, December 4th. The stock was sold at an average price of $85.24, for a total transaction of $70,663.96. Following the completion of the sale, the senior vice president now directly owns 8,101 shares in the company, valued at approximately $690,529.24. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 40.50% of the stock is currently owned by corporate insiders.
Several hedge funds and other institutional investors have recently modified their holdings of the stock. Jennison Associates LLC lifted its stake in shares of TESARO by 0.5% during the 4th quarter. Jennison Associates LLC now owns 338,919 shares of the biopharmaceutical company’s stock worth $28,086,000 after purchasing an additional 1,658 shares during the last quarter. Peregrine Capital Management LLC lifted its stake in shares of TESARO by 21.0% during the 4th quarter. Peregrine Capital Management LLC now owns 142,833 shares of the biopharmaceutical company’s stock worth $11,837,000 after purchasing an additional 24,743 shares during the last quarter. Cerebellum GP LLC purchased a new stake in shares of TESARO during the 4th quarter worth $3,354,000. State of Alaska Department of Revenue purchased a new stake in shares of TESARO during the 4th quarter worth $223,000. Finally, Fox Run Management L.L.C. purchased a new stake in shares of TESARO during the 4th quarter worth $218,000.
COPYRIGHT VIOLATION NOTICE: “TESARO Inc (TSRO) Receives Average Rating of “Hold” from Analysts” was first published by American Banking News and is the property of of American Banking News. If you are viewing this piece on another domain, it was stolen and reposted in violation of United States & international copyright and trademark legislation. The original version of this piece can be accessed at https://www.americanbankingnews.com/2018/01/27/tesaro-inc-tsro-receives-average-rating-of-hold-from-analysts.html.
TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.
Receive News & Ratings for TESARO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO and related companies with MarketBeat.com's FREE daily email newsletter.